ZA200300257B - Photodynamic treatment and UV-B irradiation of a thrombocyte suspension. - Google Patents
Photodynamic treatment and UV-B irradiation of a thrombocyte suspension. Download PDFInfo
- Publication number
- ZA200300257B ZA200300257B ZA200300257A ZA200300257A ZA200300257B ZA 200300257 B ZA200300257 B ZA 200300257B ZA 200300257 A ZA200300257 A ZA 200300257A ZA 200300257 A ZA200300257 A ZA 200300257A ZA 200300257 B ZA200300257 B ZA 200300257B
- Authority
- ZA
- South Africa
- Prior art keywords
- suspension
- radiation
- platelet
- wavelength range
- treatment
- Prior art date
Links
- 239000000725 suspension Substances 0.000 title claims description 34
- 238000002428 photodynamic therapy Methods 0.000 title description 11
- 210000001772 blood platelet Anatomy 0.000 title 1
- 241000700605 Viruses Species 0.000 claims description 41
- 238000000034 method Methods 0.000 claims description 30
- 239000003634 thrombocyte concentrate Substances 0.000 claims description 23
- 239000000126 substance Substances 0.000 claims description 20
- 230000005855 radiation Effects 0.000 claims description 17
- 239000000975 dye Substances 0.000 claims description 11
- 210000004369 blood Anatomy 0.000 claims description 9
- 239000008280 blood Substances 0.000 claims description 9
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 claims description 7
- 229950000688 phenothiazine Drugs 0.000 claims description 7
- RBTBFTRPCNLSDE-UHFFFAOYSA-N 3,7-bis(dimethylamino)phenothiazin-5-ium Chemical compound C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 RBTBFTRPCNLSDE-UHFFFAOYSA-N 0.000 claims description 6
- 238000010521 absorption reaction Methods 0.000 claims description 6
- 229960000907 methylthioninium chloride Drugs 0.000 claims description 6
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 3
- 230000035755 proliferation Effects 0.000 claims description 2
- 229950003937 tolonium Drugs 0.000 claims description 2
- HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 claims description 2
- 238000002617 apheresis Methods 0.000 claims 1
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 claims 1
- KUUVQVSHGLHAKZ-UHFFFAOYSA-N thionine Chemical compound C=1C=CC=CSC=CC=1 KUUVQVSHGLHAKZ-UHFFFAOYSA-N 0.000 description 22
- 230000002779 inactivation Effects 0.000 description 18
- 238000002474 experimental method Methods 0.000 description 12
- 241000711975 Vesicular stomatitis virus Species 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 11
- 239000010836 blood and blood product Substances 0.000 description 8
- 230000000415 inactivating effect Effects 0.000 description 8
- 210000000265 leukocyte Anatomy 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 229940125691 blood product Drugs 0.000 description 7
- 210000002381 plasma Anatomy 0.000 description 7
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 5
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- DDGMDTGNGDOUPX-UHFFFAOYSA-N 7-methyliminophenothiazin-3-amine;hydrochloride Chemical compound [Cl-].C1=C(N)C=C2SC3=CC(=[NH+]C)C=CC3=NC2=C1 DDGMDTGNGDOUPX-UHFFFAOYSA-N 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 241000710780 Bovine viral diarrhea virus 1 Species 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 208000031886 HIV Infections Diseases 0.000 description 2
- 241000709721 Hepatovirus A Species 0.000 description 2
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- PGWTYMLATMNCCZ-UHFFFAOYSA-M azure A Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 PGWTYMLATMNCCZ-UHFFFAOYSA-M 0.000 description 2
- KFZNPGQYVZZSNV-UHFFFAOYSA-M azure B Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(NC)=CC=C3N=C21 KFZNPGQYVZZSNV-UHFFFAOYSA-M 0.000 description 2
- PPBOKXIGFIBOGK-BDTUAEFFSA-N bvdv Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)C(C)C)[C@@H](C)CC)C1=CN=CN1 PPBOKXIGFIBOGK-BDTUAEFFSA-N 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000000306 component Substances 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- LXWYCLOUQZZDBD-LIYNQYRNSA-N csfv Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)[C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O)C1=CC=C(O)C=C1 LXWYCLOUQZZDBD-LIYNQYRNSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 230000003253 viricidal effect Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000710777 Classical swine fever virus Species 0.000 description 1
- 102100022641 Coagulation factor IX Human genes 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 108010076282 Factor IX Proteins 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 1
- 241000710961 Semliki Forest virus Species 0.000 description 1
- 206010051511 Viral diarrhoea Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229940050528 albumin Drugs 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- -1 azure dyes A Chemical compound 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 229950004398 broxuridine Drugs 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 238000005202 decontamination Methods 0.000 description 1
- 230000003588 decontaminative effect Effects 0.000 description 1
- 230000017858 demethylation Effects 0.000 description 1
- 238000010520 demethylation reaction Methods 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000001085 differential centrifugation Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229960004222 factor ix Drugs 0.000 description 1
- 229960000301 factor viii Drugs 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 244000309711 non-enveloped viruses Species 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 150000002926 oxygen Chemical class 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 108091069025 single-strand RNA Proteins 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 244000000009 viral human pathogen Species 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
- A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0205—Chemical aspects
- A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
- A01N1/0215—Disinfecting agents, e.g. antimicrobials for preserving living parts
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0278—Physical preservation processes
- A01N1/0294—Electromagnetic, i.e. using electromagnetic radiation or electromagnetic fields
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/19—Platelets; Megacaryocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/10—Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person
- A61K41/17—Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person by ultraviolet [UV] or infrared [IR] light, X-rays or gamma rays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
- A61L2/0082—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using chemical substances
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Wood Science & Technology (AREA)
- Environmental Sciences (AREA)
- Dentistry (AREA)
- Developmental Biology & Embryology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Electromagnetism (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- External Artificial Organs (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Materials For Medical Uses (AREA)
- Radiation-Therapy Devices (AREA)
- Apparatus For Disinfection Or Sterilisation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10031851A DE10031851B4 (de) | 2000-07-04 | 2000-07-04 | Photodynamische Behandlung und UV-B-Bestrahlung einer Thrombozyten-Suspension |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200300257B true ZA200300257B (en) | 2003-11-04 |
Family
ID=7647321
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200300257A ZA200300257B (en) | 2000-07-04 | 2003-01-09 | Photodynamic treatment and UV-B irradiation of a thrombocyte suspension. |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20040072139A1 (fr) |
| EP (1) | EP1307241B1 (fr) |
| CN (1) | CN1264577C (fr) |
| AT (1) | ATE296118T1 (fr) |
| AU (2) | AU7955601A (fr) |
| BR (1) | BR0111958A (fr) |
| CA (1) | CA2415063C (fr) |
| CZ (1) | CZ300018B6 (fr) |
| DE (2) | DE10031851B4 (fr) |
| DK (1) | DK1307241T3 (fr) |
| EA (1) | EA004246B1 (fr) |
| ES (1) | ES2241850T3 (fr) |
| HU (1) | HU226418B1 (fr) |
| MX (1) | MXPA02012663A (fr) |
| PL (1) | PL363076A1 (fr) |
| PT (1) | PT1307241E (fr) |
| SK (1) | SK1002003A3 (fr) |
| WO (1) | WO2002002152A1 (fr) |
| ZA (1) | ZA200300257B (fr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6843961B2 (en) * | 2000-06-15 | 2005-01-18 | Gambro, Inc. | Reduction of contaminants in blood and blood products using photosensitizers and peak wavelengths of light |
| US9044523B2 (en) | 2000-06-15 | 2015-06-02 | Terumo Bct, Inc. | Reduction of contaminants in blood and blood products using photosensitizers and peak wavelengths of light |
| JP4704684B2 (ja) * | 2002-02-01 | 2011-06-15 | カリディアンビーシーティ バイオテクノロジーズ，エルエルシー | 光増感剤および光のピーク波長を使用する血液および血液製剤中の汚染の減少 |
| EP1496114A1 (fr) * | 2003-07-07 | 2005-01-12 | Margraf, Stefan, Dr.med. | Procédé d'inactivation de microorganismes |
| DE102010017687A1 (de) * | 2010-07-01 | 2012-01-05 | Claas Selbstfahrende Erntemaschinen Gmbh | Verfahren zur Einstellung zumindest eines Arbeitsorganes einer selbstfahrenden Erntemaschine |
| CN109966574A (zh) * | 2016-02-02 | 2019-07-05 | 汪相伯 | 一种基于核黄素光化学法的血液制品处理系统 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3930510A1 (de) * | 1989-09-13 | 1991-03-21 | Blutspendedienst Dt Rote Kreuz | Verfahren zur inaktivierung von viren in blut und blutprodukten |
| US6348309B1 (en) * | 1989-09-13 | 2002-02-19 | Blutspendedienst Der Landesverbaende Des Deutschen Roten Kreuzes Niedersachsen, Oldenburg Und Bremen G.G.M.B.H. | Process for inactivating viruses in blood and blood products |
| US5545516A (en) * | 1990-05-01 | 1996-08-13 | The American National Red Cross | Inactivation of extracellular enveloped viruses in blood and blood components by phenthiazin-5-ium dyes plus light |
| US6077659A (en) * | 1990-05-15 | 2000-06-20 | New York Blood Center, Inc. | Vitamin E and derivatives thereof prevent potassium ion leakage and other types of damage in red cells that are virus sterilized by phthalocyanines and light |
| CA2199372A1 (fr) * | 1994-09-22 | 1996-03-28 | Raymond P. Goodrich, Jr. | Procede d'inactivation photodynamique de contaminants du sang de nature virale et bacterienne a l'aide de sensibilisants a la coumarine ou la furocoumarine |
| EP0840624B1 (fr) * | 1995-07-14 | 2007-07-25 | CAF - DCF cvba - scrl | Installation d'inactivation de contaminants viraux presents dans des produits sanguins |
| US20010053547A1 (en) * | 1995-12-04 | 2001-12-20 | Slichter Sherrill J. | Method for preparing a platelet composition |
| EP0973383A4 (fr) * | 1997-01-21 | 2001-08-22 | American Nat Red Cross | Decontamination intracellulaire et extracellulaire de sang total et de composants du sang au moyen de colorants amphiphiles phenotiazin-5-ium et de lumiere |
| US6258577B1 (en) * | 1998-07-21 | 2001-07-10 | Gambro, Inc. | Method and apparatus for inactivation of biological contaminants using endogenous alloxazine or isoalloxazine photosensitizers |
-
2000
- 2000-07-04 DE DE10031851A patent/DE10031851B4/de not_active Expired - Fee Related
-
2001
- 2001-07-04 AU AU7955601A patent/AU7955601A/xx not_active Withdrawn
- 2001-07-04 HU HU0301717A patent/HU226418B1/hu not_active IP Right Cessation
- 2001-07-04 AT AT01957701T patent/ATE296118T1/de not_active IP Right Cessation
- 2001-07-04 PL PL01363076A patent/PL363076A1/xx not_active IP Right Cessation
- 2001-07-04 DK DK01957701T patent/DK1307241T3/da active
- 2001-07-04 PT PT01957701T patent/PT1307241E/pt unknown
- 2001-07-04 CN CNB018122973A patent/CN1264577C/zh not_active Expired - Fee Related
- 2001-07-04 SK SK100-2003A patent/SK1002003A3/sk unknown
- 2001-07-04 US US10/332,108 patent/US20040072139A1/en not_active Abandoned
- 2001-07-04 BR BR0111958-3A patent/BR0111958A/pt not_active IP Right Cessation
- 2001-07-04 WO PCT/DE2001/002410 patent/WO2002002152A1/fr active IP Right Grant
- 2001-07-04 ES ES01957701T patent/ES2241850T3/es not_active Expired - Lifetime
- 2001-07-04 DE DE50106329T patent/DE50106329D1/de not_active Expired - Fee Related
- 2001-07-04 MX MXPA02012663A patent/MXPA02012663A/es active IP Right Grant
- 2001-07-04 CA CA002415063A patent/CA2415063C/fr not_active Expired - Fee Related
- 2001-07-04 EA EA200300111A patent/EA004246B1/ru not_active IP Right Cessation
- 2001-07-04 EP EP01957701A patent/EP1307241B1/fr not_active Expired - Lifetime
- 2001-07-04 AU AU2001279556A patent/AU2001279556B2/en not_active Ceased
-
2003
- 2003-01-03 CZ CZ20030015A patent/CZ300018B6/cs not_active IP Right Cessation
- 2003-01-09 ZA ZA200300257A patent/ZA200300257B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0301717A2 (hu) | 2003-08-28 |
| EA004246B1 (ru) | 2004-02-26 |
| HUP0301717A3 (en) | 2005-12-28 |
| CN1264577C (zh) | 2006-07-19 |
| EA200300111A1 (ru) | 2003-06-26 |
| US20040072139A1 (en) | 2004-04-15 |
| BR0111958A (pt) | 2003-07-01 |
| EP1307241A1 (fr) | 2003-05-07 |
| ES2241850T3 (es) | 2005-11-01 |
| CA2415063A1 (fr) | 2002-12-30 |
| DE10031851B4 (de) | 2005-10-13 |
| DK1307241T3 (da) | 2005-08-08 |
| AU2001279556B2 (en) | 2006-07-06 |
| SK1002003A3 (en) | 2003-06-03 |
| EP1307241B1 (fr) | 2005-05-25 |
| ATE296118T1 (de) | 2005-06-15 |
| AU7955601A (en) | 2002-01-14 |
| CZ300018B6 (cs) | 2009-01-14 |
| HU226418B1 (en) | 2008-12-29 |
| WO2002002152A1 (fr) | 2002-01-10 |
| PT1307241E (pt) | 2005-08-31 |
| CN1440297A (zh) | 2003-09-03 |
| MXPA02012663A (es) | 2004-07-30 |
| DE50106329D1 (de) | 2005-06-30 |
| DE10031851A1 (de) | 2002-01-24 |
| CA2415063C (fr) | 2006-10-03 |
| PL363076A1 (en) | 2004-11-15 |
| CZ200315A3 (cs) | 2003-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6214534B1 (en) | Biological compositions containing quenchers of type I and type II photodynamic reactions | |
| US6548242B2 (en) | Process for the sterilization of biological compositions and the product thereby | |
| US5120649A (en) | Photodynamic inactivation of viruses in blood cell-containing compositions | |
| US5712086A (en) | Process for transfusing cell containing fractions sterilized with radiation and a quencher of type I and type II photodynamic reactions | |
| US6087141A (en) | Process for the sterilization of biological compositions and the product produced thereby | |
| Lambrecht et al. | Photoinactivation of viruses in human fresh plasma by phenothiazine dyes in combination with visible light | |
| Horowitz et al. | Inactivation of viruses in blood with aluminum phthalocyanine derivatives | |
| US5637451A (en) | Photodynamic treatment of red blood cells with phthalocyanines and red light at higher light fluence rates is protective of red blood cells | |
| CA2163636C (fr) | Methode de sterilisation de compositions biologiques et produit ainsi obtenu | |
| Ben-Hur et al. | The photodecontamination of cellular blood components: mechanisms and use of photosensitization in transfusion medicine | |
| Gugerell et al. | Viral safety of APOSECTM: a novel peripheral blood mononuclear cell derived-biological for regenerative medicine | |
| CA2415063C (fr) | Traitement photodynamique et exposition aux rayons u.v.-b d'une suspension de plaquettes | |
| US20010046662A1 (en) | Method of inactivating pathogens in a red blood cell-containing composition | |
| Corash | Inactivation of Viruses, Bacteria, Protozoa, and Leukocytes in Labile Blood Components by Using Nucleic Acid Targeted Methods | |
| US20060269907A1 (en) | Decontamination of biological fluids using diphenylpyrilium compounds | |
| Trannoy | Pathogen inactivation in cellular blood products by photodynamic treatment | |
| Pehta | Viral Inactivation of Blood Components | |
| Rezvani-Boroujeni et al. | The Effect of Methylene Blue in Combination with Red Visible Light on Model Viruses Inactivation and Coagulation Factors in Fresh Frozen Plasma |